SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
KYNB

Kyntra Bio, Inc. (NASDAQ:KYNB)

US · Delayed Price · Currency is USD
Also listed: 0IL8.L, FGENHealthcare · Biotechnology
$1.56-$0.27 (-14.72%)
 
Market cap
$6.32M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 14, 2014
Market Cap$6.32M-81.8%
Revenue (ttm)$5.30M+104.5%
Net Income$34.88M-78.7%
EPS$8.62+1557.7%
Shares Out4.05M
PE Ratio0.18
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,379
Open$1.81
Previous Close$1.83
Day's Range$1.54 - $1.81
52-Week Range$1.54 - $10.47
Beta1.10
AnalystsHold
Price Target$28.00(+1694.87%)
Earnings DateMar 15, 2027
-13.08% (1D)
No price history available.

About KYNB

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

Address
350 Bay Street, San Francisco, CA, 94133, US
Market Cap
6 million
Employees
34
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$53.60K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating KYNB in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From KYNB’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-14.72%
5 Days
-54.25%
1 Month
-70.11%
6 Months
-77.68%
1 Year
-81.82%

$KYNB stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in KYNB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by KYNB's directors and management

Net Shares Purchased by Insiders−4k−2k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

KYNB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

KYNB Revenue by Segment or Geography

KYNB's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New KYNB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to KYNB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in KYNB

VTIVanguard Morningstar Total Stock Market ETF$411.19K
VXFVanguard Extended Market ETF$193.15K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from KYNB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
35

News check: Multiple analyst downgrades on price targets coupled with Q3 earnings miss on revenue, though some analysts maintain buy ratings.

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$53.60K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.